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ABSTRACT
Background: Linezolid (LZD), an oxazolidinone antibiotic agent, has excel-
lent activity and bioavailability against most methicillin-sensitive and methicillin-
resistant gram-positive bacteria. Although LZD is generally well tolerated, several
studies have found adverse hematologic effects, of which thrombocytopenia is of most
concern.
Objective: To investigate the risk factors for thrombocytopenia in patients
who received oral or parenteral LZD therapy between February 1 and November 30,
2010.
Methods: Data were extracted retrospectively from the electronic medical
records in our hospital information system. Thrombocytopenia was defined as either
a final platelet count of 100  109/L (criterion 1) or a 25% reduction from the
aseline platelet count (criterion 2). Risk factors were determined using logistic
egression analysis, and clinical features were predicted using receiver operating
haracteristic curves.
Results: The study included 254 patients, with mean (SD) age of 59 (17.66)
years. The duration of LZD therapy was 9.43 (5.63) days. Thrombocytopenia devel-
oped in 69 patients (27.2%), as defined by criterion 1, and in 127 patients (50%), as
defined by criterion 2. At univariate analysis, age, weight, creatinine clearance, serum
albumin concentration, baseline platelet count, daily dosage, and concomitant use of
caspofungin, levofloxacin, and meropenem were significant risk factors for thrombo-
cytopenia. At multivariate analysis and using ROC curves, daily dose18.75 mg/kg,
baseline platelet count 181  109/L, duration of LZD therapy 10 days, and
oncomitant use of caspofungin and levofloxacin were independent risk factors for
hrombocytopenia as defined by criterion 1, whereas creatinine clearance 88.39
L/min/1.73 m2, serum albumin concentration 33.5 g/L, daily dose 18.46
g/kg, and caspofungin were independent risk factors for thrombocytopenia as
efined by criterion 2.
Conclusions: The incidence of LZD-related thrombocytopenia in the Chinese
population is much higher than that suggested by the drug instructions. Low
pretreatment platelet count, low body weight, low serum albumin concentration,
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Current Therapeutic Researchlong-term drug administration, advanced age, renal insufficiency, and concomitant
use of caspofungin, levofloxacin, and meropenem have been identified as risk factors.
Although predictors have been proposed for use in clinical practice to screen for
patients at high risk who require intensified monitoring, further research on the
dosage-based pharmacokinetics and pharmacodynamics of LZD are urgently needed.
(Curr Ther Res Clin Exp. 2012;73:195–206) © 2012 Elsevier HS Journals, Inc. All
rights reserved.
Key words: baseline platelet count, daily dosage, linezolid, risk factor, serum
albumin, thrombocytopenia.Linezolid (LZD), an oxazolidinone antibiotic agent, has excellent activity and bio-
availability against most methicillin-sensitive and methicillin-resistant gram-positive
bacteria.1–3 Although LZD is generally well tolerated, studies have found associated
adverse hematologic effects such as thrombocytopenia, anemia, and hematocytopenia.
Of these, thrombocytopenia is of most concern. Linezolid has been available in China
since 2007, and many instances of LZD-associated thrombocytopenia have recently
been reported in China.4 However, the incidence of and risk factors for LZD-induced
thrombocytopenia in a large sample of Chinese have not been reported to date.
Moreover, the incidence of LZD-related thrombocytopenia varies between countries
such as the United States5,6 and Japan.7,8
The present retrospective cross-sectional study was performed to investigate the
isk factors for thrombocytopenia in adult Chinese patients who received LZD
herapy, to screen for important clinical features that can be used to predict the
ncidence of thrombocytopenia, to provide a reasonable assessment of the risk of
ZD-related thrombocytopenia in the Chinese population, and to reduce the inci-
ence of serious adverse reactions.
PATIENTS AND METHODS
This study was conducted at the 4000-bed Chinese PLA General Hospital. Patients
who received LZD, 1200 mg (600 mg q12h) via oral, parenteral, or both routes, were
examined. Data were collected from the electronic medical records in the hospital
central database between February 1 and November 30, 2010.
Exclusion criteria were as follows: (1) age 18 years; (2) blood system disease or
platelet decrease as the original disease, for example, acute nonlymphocytic leukemia,
lymphocytic leukemia, myelodysplasia, aplastic anemia, acute myeloid leukemia,
tumor being treated using chemotherapy, severe pancreatitis, hepatoblastoma, and
systemic lupus erythematosus; (3) platelet count not recorded before or after LZD
therapy; and (4) abnormal platelet count (100  109/L or 400  109/L) before
ZD therapy.
Thrombocytopenia was defined as platelet count 100  109/L (criterion 1) or
25% reduction from baseline platelet count (criterion 2) because of current lack
of uniform diagnostic criteria for LZD-induced thrombocytopenia. Criterion 1
was considered standard for severe thrombocytopenia, and criterion 2 for small
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C. Chen et al.decrease in platelet count. Therefore, the defined diseases per both criteria can be
better compared with other published data.7,9 Moreover, a more inclusive stan-
ard can better prevent severe adverse events. Variables including sex, age, body
eight, daily dosage of LZD, and duration of LZD therapy, and laboratory data
ncluding alanine aminotransferase, total bilirubin, creatinine, and albumin con-
entrations, and baseline platelet count before LZD therapy were analyzed as
andidate risk factors for thrombocytopenia.
Statistical analysis was performed using commercially available software (SAS
ersion 9.1.3; SAS Institute, Inc, Cary, North Carolina). The Student t-test (normal
istribution) or Mann-Whitney U test (non-normal distribution) was used to com-
are continuous variables, and the 2 test to compare dichotomous variables. P 
0.05 was considered statistically significant. Univariate and multiple logistic regres-
sion analyses were performed for each variable. Receiver operating characteristic
curves (ROCs) were used to estimate the sensitivity, specificity, accuracy, and cutoff
values for continuous variables that closely related to thrombocytopenia in multiple
logistic regression analysis.
RESULTS
Patient Data
During the study, 512 patients were screened. According to the exclusion
riteria, 254 patients (169 men and 85 women; mean [SD] age, 59.0 [17.7] years
range, 18–95 years]) were included in the study. Duration of LZD therapy was
.43 (5.63) days (range, 1.5–35.5 days). Linezolid-induced thrombocytopenia
as determined in 69 patients (27.2%) on the basis of criteria 1, and 127 patients
50%) according to criteria 2. In 27 patients (10.6%), thrombocytopenia was
rade III or IV according to the World Health Organization assessment of acute
nd subacute adverse performance and indexing standards (grade III, 26–49 
09/L; and grade IV, 25  109/L). Seventeen patients (6.7%) required platelet
transfusions.
Risk of Thrombocytopenia
Sixteen variables potentially associated with development of thrombocytopenia
ere tested using univariate analysis. For thrombocytopenia defined using criterion 1,
ariables including age, weight, creatinine clearance, serum albumin concentration,
aily dosage, baseline platelet count, duration of medication, and levofloxacin, mero-
enem, and caspofungin therapy exhibited a statistically significant difference be-
ween patients with or without thrombocytopenia. For thrombocytopenia defined
sing criterion 2, similar results were obtained except for the baseline platelet count,
hich was not statistically significant different between patients with or without
hrombocytopenia (Table I).
At univariate logistic regression 7 variables including age, weight, creatinine
learance, serum albumin concentration, daily dosage, baseline platelet count, and
aspofungin therapy were significant risk factors for LZD-associated thrombocytope-
ia as defined using criterion 1, whereas 9 variables including age, weight, creatinine
197
Table I. Demographic and clinical data.
Variable
25% Reduction from Baseline Platelet Count Final Platelet Count 100  109/L
Patients With
Thrombocytopenia
(n  127)
Patients Without
Thrombocytopenia
(n  127) P
Patients With
Thrombocytopenia
(n  69)
Patients Without
Thrombocytopenia
(n  185) P
Demographic data
Sex, No. (%) 0.35* 0.57*
Male 81 (63.78) 88 (69.29) 44 (63.77) 125 (67.57)
Female 46 (36.22) 39 (30.71) 25 (36.23) 60 (32.43)
Age, y 61.36 (17.11) 56.83 (18.03) 0.04† 63.49 (15.97) 57.45 (18.06) 0.02†
No. of pts (missing) 127 (0) 127 (0) NA 69 (0) 185 (0) NA
Weight, kg 62.15 (12.48) 67.15 (13.45) 0.002† 61.70 (13.18) 65.75 (13.06) 0.03†
No. of pts (missing) 127 (0) 127 (0) NA 69 (0) 185 (0) NA
Laboratory data
Alanine aminotransferase (U/L) 33.69 (42.93) 34.86 (42.87) 0.26‡ 30.24 (27.55) 35.79 (47.27) 0.31‡
No. of pts (missing) 127 (0) 126 (1) NA 69 (0) 184 (1) NA
Total bilirubin (mol/L) 20.12 (31.82) 15.48 (14.75) 0.63‡ 18.01 (17.52) 17.76 (27.30) 0.38‡
No. of pts (missing) 127 (0) 124 (3) NA 69 (0) 182 (3) NA
Creatinine clearance, mL/min 87.67 (59.00) 106.90 (58.28) 0.004‡ 84.37 (63.12) 102.07 (57.26) 0.009‡
No. of pts (missing) 127 (0) 126 (1) NA 69 (0) 184 (1) NA
Albumin, g/L 31.89 (5.12) 34.45 (10.08) 0.01‡ 31.34 (5.27) 33.84 (8.79) 0.005‡
No. of pts (missing) 126 (1) 123 (4) NA 68 (1) 181 (4) NA
Daily dose, mg/kg 19.99 (4.18) 17.83 (4.39) 0.001‡ 20.11 (4.14) 18.46 (4.44) 0.002‡
No. of pts (missing) 127 (0) 127 (0) NA 69 (0) 185 (0) NA
Baseline platelet count, 109/L 212.50 (76.96) 224.71 (72.85) 0.12‡ 176.96 (61.97) 234.14 (73.68) 0.001‡
No. of pts (missing) 127 (0) 127 (0) NA 69 (0) 185 (0) NA
(continued)
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Table I (continued).
Variable
25% Reduction from Baseline Platelet Count Final Platelet Count 100  109/L
Patients With
Thrombocytopenia
(n  127)
Patients Without
Thrombocytopenia
(n  127) P
Patients With
Thrombocytopenia
(n  69)
Patients Without
Thrombocytopenia
(n  185) P
Treatment duration, d 10.31 (5.64) 8.55 (5.54) 0.002‡ 10.52 (5.01) 9.02 (5.83) 0.007‡
No. of pts (missing) 127 (0) 127 (0) NA 69 (0) 185 (0) NA
Anti-infective agent coadministered with
linezolid, No. (%)
Nuoroquinolone 47 (37.01) 37 (29.13) 0.18* 29 (42.03) 55 (29.73) 0.06*
Moxifloxacin 14 (11.02) 14 (11.02) 0.99 9 (13.04) 19 (10.27) 0.53*
Levofloxacin 33 (25.98) 20 (15.75) 0.04* 20 (28.99) 33 (17.84) 0.05*
-Lactams 63 (49.61) 61 (48.03) 0.80* 34 (49.28) 90 (48.65) 0.93*
Piperacillin and tazobactam sodium 15 (11.81) 14 (11.02) 0.84* 5 (7.25) 24 (12.97) 0.20*
Cefoperazone and sulbactam sodium 35 (27.56) 26 (20.47) 0.19* 22 (31.88) 39 (21.08) 0.07*
Carbapenems 75 (59.06) 55 (43.31) 0.01* 42 (60.87) 88 (47.57) 0.06*
Imipenem and cilastatin sodium 21 (16.54) 19 (14.96) 0.73* 10 (14.49) 30 (16.22) 0.74*
Meropenem 55 (43.31) 55 (43.31) 0.009 31 (44.93) 59 (31.89) 0.05*
Antifungal agents 62 (48.82) 48 (37.80 0.08* 35 (50.72) 75 (40.54) 0.15*
Voriconazole 14 (11.02) 12 (9.45%) 0.68* 9 (13.04) 17 (9.19) 0.37*
Caspofungin 26 (20.47) 11 (8.66) 0.008* 16 (23.19) 21 (11.35) 0.02*
Fluconazole 29 (22.83) 25 (19.69) 0.54* 16 (23.19) 38 (20.54) 0.65*
Unless otherwise noted, data are given as mean (SD).
NA  not applicable; pts  patients.
*2 test.
†Student t test.
‡Mann-Whitney U test.
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Current Therapeutic Researchclearance, serum albumin concentration, daily dosage, treatment duration, and levo-
floxacin, meropenem, and caspofungin therapy were significantly correlated with
thrombocytopenia as defined using criterion 2 (Table II). According to regression
coefficient analysis, whereas creatinine clearance, serum albumin concentration, base-
line platelet count, and weight were protective factors, age and daily dosage were risk
factors.
At multivariate logistic regression analysis, baseline platelet count, daily dosage,
duration of medication, and caspofungin and levofloxacin therapy were independent
Table II. Risk factors for thrombocytopenia selected using logistic regression.*
Risk Factor
25% Reduction From
Baseline Platelet Count
Final Platelet
Count 100  109/L
OR 95% CI P OR 95% CI P
Analysis by univariate logistic regression
Age, y 1.01 1.00–1.03 0.04 1.02 1.00–1.04 0.02
Weight, kg 0.97 0.95–0.99 0.003 0.98 0.95–1.00 0.03
Creatinine clearance, mL/min 0.99 0.99–1.00 0.01 0.99 0.99–1.00 0.04
Albumin, g/L 0.94 0.90–0.99 0.01 0.94 0.89–0.99 0.01
Daily dose, mg/kg 1.13 1.06–1.20 0.002 1.09 1.02–1.16 0.009
Baseline platelet count, 109/L 1.00 0.99–1.00 0.20 0.99 0.98–0.99 0.001
Treatment duration, d 1.06 1.01–1.11 0.02 1.05 1.00–1.10 0.06
Moxifloxacin 1.00 0.46–2.19 0.99 1.31 0.56–3.05 0.53
Levofloxacin 1.88 1.01–3.49 0.046 1.88 0.99–3.57 0.05
Piperacillin and tazobactam sodium 1.08 0.5–2.34 0.84 0.52 0.19–1.43 0.21
Cefoperazone and sulbactam sodium 1.48 0.83–2.64 0.19 1.75 0.95–3.25 0.07
Imipenem and cilastatin sodium 1.13 0.57–2.21 0.73 0.88 0.40–1.90 0.74
Meropenem 2.01 1.19–3.39 0.009 1.74 0.99–3.07 0.054
Voriconazole 1.19 0.53–2.68 0.68 1.48 0.63–3.50 0.37
Caspofungin 2.71 1.28–5.77 0.009 2.36 1.15–4.85 0.02
Fluconazole 1.21 0.66–2.20 0.54 1.17 0.60–2.27 0.65
Selected by multivariate logistic analysis
Creatinine clearance, mL/min 0.10 0.99–1.00 0.04 NA NA NA
Albumin, g/L 0.95 0.90–0.19 0.03 NA NA NA
Daily dose, mg/kg 1.12 1.05–1.20 0.001 1.08 1.01–1.16 0.03
Baseline platelet count, 109/L NA NA NA 0.99 0.98–0.99 0.001
Treatment duration, d NA NA NA 1.06 1.01–1.12 0.03
Caspofungin 2.81 1.28–6.20 0.01 2.41 1.09–5.3 0.04
Levofloxacin NA NA NA 2.00 0.97–4.11 0.03
CI  confidence interval; NA  not available; OR  odds ratio.
*P  0.05.risk factors for LZD-induced thrombocytopenia as defined using criterion 1, whereas
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therapy were significantly associated with LZD-induced thrombocytopenia as defined
using criterion 2 (Table II).
Critical Features of Thrombocytopenia as Predicated Using ROC
Curves
At logistic regression multivariate analysis, baseline platelet count, daily dosage,
nd duration of medication, which related to thrombocytopenia as defined using
riterion 1, were included to calculate the area under the ROC curve (AUC). The
aximum Youden index was 0.44, and the AUC was 0.76. According to the cutoff
oint, the daily dose was 18.75 mg/kg, the baseline platelet count was 181  109/L,
and the duration of medication was 10 days.
Creatinine clearance, serum albumin concentration, and daily dosage, as related to
thrombocytopenia defined using criterion 2, were used to calculate the AUC. The
maximum Youden index was 0.37, and the AUC was 0.71. According to the cutoff
point, creatinine clearance was 88.39 mL/min/1.73 m2, the serum albumin concen-
ration was 33.5 g/L, and the daily dose was 18.46 mg/kg.
DISCUSSION
The mechanisms underlying LZD-related hematologic toxicity remain unclear, and
the reported incidence of LZD-induced thrombocytopenia varies. Attassi et al5 and
Orrick et al6 have reported the incidences of LZD-induced thrombocytopenia in
western countries. When thrombocytopenia was defined as a 30% decrease in
platelet count, similar incidences were observed: 47% (9 of 19 patients)5 vs 48% (23
f 48 patients).6 When thrombocytopenia was defined as platelet count 100 
109/L, thrombocytopenia was 32% (6 of 19 patients)5 vs19% (9 of 48 patients).6
Thrombocytopenia has been reported in 7 of 42 patients (16.7%) by Niwa et al7 in
Japan. Although criterion 2 in the present study is more inclusive, all of these studies
included a relatively small sample size. Recently, another report from Japan reported
drug-induced thrombocytopenia (defined as 100  109/L or a 30% reduction from
aseline) in 128 of 331 included patients (38.7%).8
The present study reports LZD-induced thrombocytopenia in the Chinese popu-
ation on the basis of a survey of 254 patients. Incidence of thrombocytopenia defined
sing criterion 2 was much higher than that defined using criterion 1: 50% vs 27.2%.
he results indicated that a small decrease in platelet count is common, and the
ndependent risk factors are different for a small decrease in platelet count vs severe
hrombocytopenia. In addition, physicians should be concerned about hemorrhagic
endency. The results of the present study are consistent with those of previous
eports; however, the incidence of thrombocytopenia reported herein is much higher
han that in LZD-treated adult patients with substantially low platelet counts in
hase III comparator-controlled trials.10 Such differences may be attributed in part to
inclusion of patients with comorbid conditions, who were excluded from the phase III
clinical trials. Inasmuch as different criteria result in a significantly different inci-
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Current Therapeutic Researchdence, it is necessary to unify the standard in this field to facilitate comparisons
between various studies.
In general, the cutoff point for risk factors is determined by the well-known human
pathologic classification, such as age 65 years (elderly group), creatinine clearance
30 or 50 mL/min/1.73 m2 (grading the severity of renal dysfunction), and baseline
latelet count 200  109/L (normal), rather than analysis of clinical data. The
resent study considered thrombocytopenia as a drug-induced disease, and used the
ndependent risk factors as predictors. The ROC curve was used to predict the cutoff
oint with good sensitivity and specificity for development of thrombocytopenia. The
UC 0.5 under both defining criteria is a good initial predictive (diagnostic)
alue.11 With a daily dose of18.75 mg/kg (P 0.005; odds ratio [OR], 2.70; 95%
confidence interval [CI], 1.54–4.74), baseline platelet count 181  109/L (P 
0.001; OR, 3.93; 95% CI, 2.24–6.90), or number of treatment days10 (P 0.04;
OR, 1.77; 95% CI, 1.02–3.09), patients are susceptible to thrombocytopenia or
bleeding risk, and blood monitoring should be more frequent. With creatinine
clearance 88.39 mL/min/1.73 m2 (P  0.005; OR, 2.06; 95% CI, 1.25–3.39),
erum albumin concentration 33.5 g/L (P  0.049; OR, 1.67; 95% CI, 1.00–
.77), daily dose of LZD18.46 mg/kg (P 0.001; OR, 2.72; 95% CI, 1.64–4.50),
patients are at risk of a small decrease in platelet count. Because these clinical data are
easy to obtain, they are useful in clinical practice to screen high-risk patients for
intensified monitoring.
In the present study, creatinine concentration was chosen as the indicator of renal
function, and its clearance rate was calculated using the Cockcroft-Gault formula. The
results indicated that thrombocytopenia may develop when creatinine clearance is at
its lower limit, while there are yet no signs or symptoms of renal insufficiency.
Moreover, we observed a higher incidence of thrombocytopenia in the group with
severe renal impairment. With creatinine clearance 30 mL/min/1.73 m2, the OR is
2.92. This finding is similar to the results of a retrospective case-control study that
found a higher incidence in the group with end-stage renal disease.12 Matsumoto
et al13,14 have reported that the clearance rate of LZD depends on creatinine clearance
nd that thrombocytopenia is concentration dependent, which suggests that the drug
oncentration may be elevated in patients with renal insufficiency, and the probability
f thrombocytopenia is hence increased. Creatinine clearance 60 mL/min and/or
rea nitrogen concentration 23 mg/dL indicate insufficient renal function due to
rug-induced thrombocytopenia. Brier et al15 have reported that the levels of 2 in
vivo metabolites of LZD, PNU-142586 and PMU-142300, in patients with renal
insufficiency are 10-fold higher than in patients with normal renal function. How-
ever, the clinical significance of accumulation of these metabolites needs to be further
studied.
Serum albumin concentration has been listed as one of the indicators because we
have noticed that drug-induced thrombocytopenia rarely develops in patients who
received human serum albumin during LZD therapy. That the serum albumin
concentration is significantly negatively related to development of thrombocytopenia
suggests that serum albumin may be a protective factor. The ROC results also
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C. Chen et al.indicated that serum albumin concentration 33.5 g/L is associated with a high
incidence of thrombocytopenia. However, the underlying mechanism of specific
protection by serum albumin needs further study.
The daily dose in the present study was determined on the basis of body weight.
Because the total daily dosage of LZD in most patients was 1200 mg, the differences
in daily dosage resulted from the variance in patients’ body weight. Daily dosage is
an independent risk factor closely associated with the incidence of thrombocytopenia,
which suggests that LZD-related thrombocytopenia depends on drug concentration.
Univariate analysis indicating that body weight is a protective factor against throm-
bocytopenia also supports this conclusion. The results of the ROC cutoff point
suggest that thrombocytopenia is more likely to develop in patients receiving a daily
dose of LZD 18.46 mg/kg and with body weight 65 kg. Takashi et al8 have also
reported that a daily dose 22 mg/kg is an important risk factor for LZD-related
thrombocytopenia. Abe et al16 have also indicated that body weight was an influential
ovariate on creatinine clearance and that the distribution volume was affected by
ody weight.
The recommended duration of LZD treatment is 10 to 14 days. One study has
eported that prolonged use of LZD (14 days) increased the risk of thrombocyto-
enia from 2.9% (36 of 1243 patients) to 4.1% (19 of 461 patients).17 Birmingham
t al18 have also reported that LZD-associated thrombocytopenia is closely related to
he duration of treatment. The incidence of thrombocytopenia was 1.9% when
reatment duration was 14 days, 5.1% when treatment duration was between 15
nd 28 days, and 7.4% when treatment duration was 28 days. The present study
urther confirmed the findings of these reports that medication duration is closely
elated to development of thrombocytopenia, and is an independent risk factor, as
evealed at multivariate analysis. The ROC curve indicates that treatment duration
10 days is more likely to cause thrombocytopenia. Therefore, the frequency of
linical blood tests should be increased in patients receiving longer treatment, and
rolonged and high-dose drug use should be avoided in patients at risk of bleeding.
Baseline platelet count has also been reported as a risk factor for thrombocytopenia.
hereas Grau et al9 reported that thrombocytopenia is more likely to develop in
patients with baseline platelet count 240.7  109/L (8 of 18 patients [44.4%])
ompared with that in other patients (4 of 31 [12.9%]) (P  0.02), baseline platelet
ount was considered the only thrombocytopenia-related risk factor in another
tudy.17 The present study has confirmed that baseline platelet count is an indepen-
dent risk factor for severe thrombocytopenia, which indicates that baseline platelet
count is closely related to LZD-induced severe thrombocytopenia, although it has
little connection with the small decrease in platelet count. Similar to the results of
previous studies, on the basis of ROC curve prediction, we found that patients with
baseline platelet count 181  109/L are more likely than others to develop
thrombocytopenia (45.9% [39 of 85] vs 17.8% [30 of 169]; P  0.001; OR, 3.93;
95% CI, 2.24–6.90).
In the present study, concomitant use of anti-infective drugs and LZD in the
hospital was investigated. These concomitantly administered medications included
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Current Therapeutic Researchcarbapenem (51.18%), -lactam (48.82%), antifungal (43.31%), and fluoroquinolone
(33.07%) agents. Nine anti-infective drugs, 7 of which may affect platelet count
according to official recommendation, were analyzed as potential risk factors. Data
indicated that levofloxacin, meropenem, and caspofungin could increase the risk of a
small reduction in platelet count. In particular, levofloxacin and caspofungin are
independent risk factors for LZD-induced thrombocytopenia. These findings suggest
that concomitant use of levofloxacin, meropenem, and caspofungin with LZD may
aggregate and enhance thrombocytopenia. Takahashi et al8 also indicated that con-
omitant use of fluoroquinolone is a risk factor for LZD-induced thrombocytopenia
P  0.009; relative risk ratio, 1.48; 95% CI, 1.05–2.08). Therefore, more attention
hould be paid to the development of thrombocytopenia when LZD is used with other
nti-infective medications, and selection of concomitantly used drugs should be
ependent on the state of disease and drug characteristics.
In Japanese patients with renal dysfunction, LZD could cause adverse effects of
evere thrombocytopenia.19 Moreover, Sasaki et al20 have reported that platelet
profiles are not determined only by exposure to LZD and that there is substantial
variability in individual sensitivity to LZD. In a study from the United States, the
overall rate of thrombocytopenia in patients receiving LZD therapy was found to be
higher than that in phase III clinical trials.21 In contrast to our study, the incidence
of thrombocytopenia was low in patients receiving LZD in a matched cohort study
performed at the Upstate New York Veterans Affairs Healthcare Network.22 Other
reports have also indicated that the incidence of LZD-induced thrombocytopenia
varies from 2.4% to 64.7%.20 Considered together, the differences between Chinese
atients and patients of other races/ethnicities may contribute to the diverse effects of
ZD in different patients.
CONCLUSION
The present study is the first analysis of risk factors for LZD-induced thrombocyto-
penia in a large Chinese population sample, and is the first to attempt to predict
thrombocytopenia risk using the ROC curve. The incidence of LZD-related throm-
bocytopenia in our Chinese population was much higher than that suggested by the
drug instructions. Low pretreatment platelet count, low body weight, low serum
albumin concentration, long-term drug administration, advanced age, renal insuffi-
ciency, and concomitant use of caspofungin, levofloxacin, and meropenem are risk
factors. Although there are predictors with good prospects for use in clinical practice
to screen high-risk patients for intensified monitoring, further research on the
dosage-based pharmacokinetics and pharmacodynamics of LZD are urgently needed.
Recent studies have found that thrombocytopenia is positively correlated with plasma
concentration of LZD,23 and we have established a method to determine the LZD
concentration in human plasma. Therefore, according to pharmacokinetics, LZD
dosage can be adjusted according to body weight to reduce the incidence of throm-
bocytopenia. Moreover, testing the effects of LZD metabolites on thrombocytopoiesis
may contribute to understanding the mechanisms involved in thrombocytopenia.
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